Kuehn Law Encourages HA, ICVX, PXD, and HARP Investors to Contact Law Firm
19 janv. 2024 13h15 HE
|
KUEHN LAW, PLLC
Kuehn Law investigates HA, ICVX, PXD, HARP mergers, seeks to protect shareholder interests. Shareholders urged to contact the firm.
HARP Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Harpoon Therapeutics to Merck
08 janv. 2024 09h25 HE
|
Wohl & Fruchter LLP
We are investigating the fairness of the sale of Harpoon Therapeutics to Merck for $23.00 per share in cash.
Harpoon Therapeutics Announces Completion of Planned Patient Enrollment in Phase 1 Study of HPN217 in Relapsed/Refractory Multiple Myeloma
27 juin 2023 07h30 HE
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., June 27, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced...
Harpoon Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
11 mai 2023 16h30 HE
|
Harpoon Therapeutics
Enrollment for HPN217 (BCMA) and HPN328 (DLL3) remain on track, with data updates and selection of recommended Phase 2 doses for both ongoing clinical programs planned in 2023 Five preclinical...
Harpoon Therapeutics Presents Preclinical Results for Novel T Cell Engagers HPN217 and HPN328 at AACR 2023
18 avr. 2023 13h30 HE
|
Harpoon Therapeutics
Preclinical results for HPN328 suggest potential for long-term anti-tumor immunity and durable responses in patients, as well as utility of combining anti-PD-L1 antibodies to enhance anti-tumor...
Harpoon Therapeutics Presents Data for New ProTriTAC™ Development Candidates in TROP2- and ITGB6-expressing Solid Tumors at AACR 2023
17 avr. 2023 13h30 HE
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today presented...
Harpoon Therapeutics to Participate in the Canaccord Horizons in Oncology Conference
10 avr. 2023 16h05 HE
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., April 10, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced...
Harpoon Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
27 mars 2023 16h05 HE
|
Harpoon Therapeutics
HPN217 (BCMA) and HPN328 (DLL3) enrollment on track, with data updates and selection of recommended Phase 2 doses for both active clinical programs planned in 2023 Completion of $25 million...
Harpoon Therapeutics Announces Closing of $25 Million Private Placement
27 mars 2023 16h02 HE
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., March 27, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP) (the “Company”), a clinical-stage immuno-oncology company developing novel T cell engagers,...
Harpoon Therapeutics Announces Acceptance of Five Abstracts for Presentation at AACR Annual Meeting 2023
14 mars 2023 18h21 HE
|
Harpoon Therapeutics
Preclinical abstracts for investigational T cell engagers, HPN328 and HPN217, in mouse models provide further validation of Harpoon’s proprietary Tri-specific T cell Activating Construct (TriTAC®)...